Nov 02

Beyond Biotech Podcast: Natural Killer Cells

Artiva Biotherapeutics’ CEO, Fred Aslan, M.D. was featured on the Beyond Biotech Podcast hosted by Labiotech.eu to discuss recent milestones including:

  • Demonstrating the potential for efficacy and safety with natural killer (NK) cells in two cancer clinical trials, and
  • Receiving FDA clearance for an IND for lupus – marking a first for an allogeneic, off-the-shelf NK or CAR-T cell therapy in autoimmune disease.

AlloNK (also known as AB-101) is a non-genetically modified, cord blood-derived, allogeneic, cryopreserved, ADCC-enhancing NK cell therapy candidate for use in combination with monoclonal antibodies or innate-cell engagers in the outpatient setting.

Listen to the podcast here.

 

Recent Posts

See All

Pharmaceutical Manufacturer Q&A: Artiva Allogeneic NK Cell Therapies for Treating Autoimmune Disease

In this interview with Pharmaceutical Manufacturer, Artiva CEO Fred Aslan, M.D., discusses the unique advantages of natural killer (NK) cell therapies and the company’s mission to bring scalable, off-the-shelf treatments to patients with autoimmune diseases. The Q&A explores how Artiva’s AlloNK® platform—comprising non-genetically modified, cryopreserved NK cells combined with disease-targeting monoclonal antibodies—could offer a more...

GEN: The Body’s Delta Force: Natural Killer Cells Re-Emerge

In a new feature published by GEN (Genetic Engineering & Biotechnology News), natural killer (NK) cells are in the spotlight showcasing their potential as the next generation of immunotherapies. This article explores how scientific and technological advances are helping cell therapy developers harness NK cells to expand the reach of cell therapy beyond oncology and...

The Bio Report Podcast: Turning Natural Killers into Off-the-Shelf Therapies for Autoimmune Disease

NK cells, part of the innate immune system, serve as the body’s first line of defense. These cells can recognize and kill abnormal or infected cells. As therapies, they have the advantage over CAR-T and other cell therapies because they can be used off-the-shelf without undergoing gene editing or other genetic modifications. They also don’t...